Titration schedule planner

GLP-1 Titration Schedule Planner

Generate a personalized week-by-week titration calendar for any GLP-1 medication using the exact dose-escalation schedule from each drug's FDA Prescribing Information. Select your medication, choose a start date, and optionally indicate your current dose to see only the remaining schedule.

Important: Your prescriber may adjust this schedule based on your tolerance. This is the standard FDA-label protocol — do not change doses without medical guidance. If side effects are intolerable at any step, contact your prescriber before the next increase.

Wegovy (semaglutide 2.4 mg) — titration calendar

Maintenance dose
2.4 mg weekly
Weeks to maintenance
16 weeks
First maintenance dose
Nov 3, 2026
WeekDate rangeDosePen colorNotes
1Jul 14, 2026 Jul 20, 20260.25 mg weeklyLight blueStarting dose — dose-escalation phase
2Jul 21, 2026 Jul 27, 20260.25 mg weeklyLight blueStarting dose — dose-escalation phase
3Jul 28, 2026 Aug 3, 20260.25 mg weeklyLight blueStarting dose — dose-escalation phase
4Aug 4, 2026 Aug 10, 20260.25 mg weeklyLight blueStarting dose — dose-escalation phase
5Aug 11, 2026 Aug 17, 20260.5 mg weeklyRed-violet
6Aug 18, 2026 Aug 24, 20260.5 mg weeklyRed-violet
7Aug 25, 2026 Aug 31, 20260.5 mg weeklyRed-violet
8Sep 1, 2026 Sep 7, 20260.5 mg weeklyRed-violet
9Sep 8, 2026 Sep 14, 20261 mg weeklyYellow
10Sep 15, 2026 Sep 21, 20261 mg weeklyYellow
11Sep 22, 2026 Sep 28, 20261 mg weeklyYellow
12Sep 29, 2026 Oct 5, 20261 mg weeklyYellow
13Oct 6, 2026 Oct 12, 20261.7 mg weeklyTeal
14Oct 13, 2026 Oct 19, 20261.7 mg weeklyTeal
15Oct 20, 2026 Oct 26, 20261.7 mg weeklyTeal
16Oct 27, 2026 Nov 2, 20261.7 mg weeklyTeal
17Nov 3, 2026 Nov 9, 20262.4 mg weeklyDark blueMAINTENANCEMaintenance dose reached
18Nov 10, 2026 Nov 16, 20262.4 mg weeklyDark blueMAINTENANCEMaintenance dose reached
19Nov 17, 2026 Nov 23, 20262.4 mg weeklyDark blueMAINTENANCEMaintenance dose reached
20Nov 24, 2026 Nov 30, 20262.4 mg weeklyDark blueMAINTENANCEMaintenance dose reached

How the planner works

Every dose, duration, and pen color in this planner comes directly from the FDA Prescribing Information (PI) for each medication. The planner does not invent or modify doses — it generates a calendar view of the exact FDA-label protocol.

  • Wegovy (semaglutide) [1]: 16-week titration from 0.25 mg to 2.4 mg maintenance, in 4-week steps.
  • Ozempic (semaglutide) [2]: 4-week start at 0.25 mg, then 0.5 mg, with optional increases to 1.0 mg and 2.0 mg.
  • Zepbound / Mounjaro (tirzepatide) [3][4]: 16-week titration from 2.5 mg to 15 mg maximum, increasing by 2.5 mg every 4 weeks.
  • Foundayo (orforglipron) [5]: Daily oral tablet. 12-week titration from 3 mg to 36 mg maintenance.

Important warning

Your prescriber may adjust this schedule based on your tolerance. This is the standard FDA-label protocol. Do not change doses without medical guidance. If you are experiencing intolerable side effects at any dose level, contact your prescriber before your next scheduled increase — they may recommend staying at the current dose for additional weeks or reducing the dose.

What this planner does NOT do

  • It does not provide medical advice or replace a conversation with your prescriber.
  • It does not account for individual tolerance — the FDA labels include “as tolerated” language that your prescriber will apply to your situation.
  • It does not generate prescriptions or medication orders.
  • It does not track actual injection/pill dates — it shows the planned schedule for reference.

Important disclaimer

This planner is for educational purposes only and does not constitute medical advice or a prescription. The titration schedules shown are the standard FDA-label protocols. Your actual titration may differ based on your clinical response, tolerance, and your prescriber's judgment. Never adjust your medication dose without consulting your prescriber.

References

  1. 1.Novo Nordisk. Wegovy (semaglutide) injection, for subcutaneous use — Prescribing Information. Section 2.1: Recommended Dosage. FDA / Drugs@FDA. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
  2. 2.Novo Nordisk. Ozempic (semaglutide) injection, for subcutaneous use — Prescribing Information. Section 2.1. FDA / Drugs@FDA. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s020lbl.pdf
  3. 3.Eli Lilly and Company. Zepbound (tirzepatide) injection, for subcutaneous use — Prescribing Information. Section 2.1. FDA / Drugs@FDA. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215866s000lbl.pdf
  4. 4.Eli Lilly and Company. Mounjaro (tirzepatide) injection, for subcutaneous use — Prescribing Information. Section 2.1. FDA / Drugs@FDA. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866Orig1s000lbl.pdf
  5. 5.Eli Lilly and Company. Foundayo (orforglipron) tablets — Prescribing Information. FDA / Drugs@FDA. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218226s000lbl.pdf

Related tools and research

Data freshnessLast verified ·Next review ·Cadence: annual

Source: FDA prescribing information titration schedules for Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo. The build fails if this date goes stale per the freshness check (npm run check:tool-freshness), so the value above is always current.

Ready to start? Vetted GLP-1 providers

Vetted telehealth providers that prescribe GLP-1 online.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

7.1

Bodybuilding Health+

Fitness-brand compounded GLP-1 with hormone and performance programs

7.4

Brightmeds

Compounded or brand GLP-1 bundled with TRT and peptides for men

6.4

Direct Meds

Listed for transparent disclosure — see FDA warning and BBB complaint pattern before considering